PDCD1 and non-small cell lung carcinoma: Immunotherapy based on immune checkpoints, such as programmed cell death 1 (PD-1) and programmed cell death ligand 1 (PD-L1), has recently offered a new approach to NSCLC treatment and has led to longer overall survival (OS) for some patients, especially those without sensitivity to therapies targeting mutations in oncogenic driver genes.